Overall, this is a highly reassuring statement. The company has successfully navigated the complexities of its transformational acquisitions (Peters Surgical and Syntacoll) while maintaining top-line momentum in its legacy portfolio. Excellent cash generation which allows for the reduction of debt. I think this would be acquired by a private equity in the next 1 year as the valuation gap vs peers is significant. Especially now that the integration is going to plan and the balance sheet is removing leverage this is a highly attractive business. The legacy AMS business grew at 10% which was quite impressive and provides excellent underpinnings for the future. Despite the shares being below my purchase price of 2.15, I am quite positive on this one.